ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 60 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 90 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 120 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - תמיסה להזרקה - pasireotide as diaspartate 0.3 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - תמיסה להזרקה - pasireotide as diaspartate 0.6 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - תמיסה להזרקה - pasireotide as diaspartate 0.9 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide acetate - אבקה וממס להכנת תרחיף להזרקה - lanreotide acetate 0.03 g/vial - lanreotide - lanreotide - treatment of acromegaly (when the treatment of growth hormone is not normalized after surgery and/or radiotherapy). treatment of the clinical symptoms of carcinoid tumors (after a test injection). treatment of primary thyrotropic adenomas responsible for hypethyroidism as a preparation for / or as a complement to surgery and/or radiotherapy or where these therapies are unsuitable.

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as embonate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as embonate 20 mg/vial - pasireotide

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as embonate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as embonate 40 mg/vial - pasireotide

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as embonate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as embonate 60 mg/vial - pasireotide